Submitted by Anonymous (not verified) on Mon, 05/07/2018 - 20:27
FDA Awards SPA Letter to NeuroRx for Pivotal Studies of NRX-101MD Magazine“I think it's becoming increasingly apparent that 50 years of serotonergic drugs have benefitted, at most, half of the people that need them,” Jonathan Javitt MD, MPH, the chief executive officer of NeuroRx, told MD